BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27053606)

  • 21. [Prokaryotic expression of HPV 16 L1 gene and identification of its immune activity].
    Hao DF; Ma ZH; Wang YP; Rexidan ; Zhang FC
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):428-31. PubMed ID: 15989783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phylogeny and In Silico Structure Analysis of Major Capsid Protein (L1) Human Papillomavirus 45 from Indonesian Isolates.
    Pradini GW; Sahiratmadja E; Suhandono S; Sudigdoadi S; Yusuf M; Firdaus ARR; Susanto H
    Asian Pac J Cancer Prev; 2020 Sep; 21(9):2517-2523. PubMed ID: 32986347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
    Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
    J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Preliminary research of induction of the multiple HPV antibody by HPV L1 type conserved sequence aimed at human papillomavirus major protein].
    Lin B; Wang X; Zhang Y; Cheng H; Hu L
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2011 Oct; 28(5):982-7. PubMed ID: 22097268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.
    Kuck D; Leder C; Kern A; Müller M; Piuko K; Gissmann L; Kleinschmidt JA
    Vaccine; 2006 Apr; 24(15):2952-65. PubMed ID: 16414157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
    Pineo CB; Hitzeroth II; Rybicki EP
    Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58.
    Xu WX; Wang J; Tang HP; He YP; Zhu QX; Gupta SK; Gu SH; Huang Q; Ji CN; Liu LF; Li GL; Xu CJ; Xie Y
    Sci Rep; 2016 Oct; 6():34686. PubMed ID: 27708433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of antibody response to HPV 16 and HPV 18 antigens in Tunisian patients.
    Achour M; Kahla S; Zeghal D; Kochbati L; Mongi M; Zouari F; Oueslati R
    Viral Immunol; 2009 Feb; 22(1):7-16. PubMed ID: 19210223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variability of human papillomavirus type 66 L1 gene among women presenting for cervical cancer screening in Chile.
    Balanda M; Fernández J; Vergara N; Campano C; Arata L; Martín HS; Ramírez E
    Med Microbiol Immunol; 2019 Dec; 208(6):757-771. PubMed ID: 31165237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
    Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic DNA immunization against multiple papillomavirus types.
    Gasparić M; Rubio I; Thönes N; Gissmann L; Müller M
    Vaccine; 2007 Jun; 25(23):4540-53. PubMed ID: 17485151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A molecular dynamics study of loop fluctuation in human papillomavirus type 16 virus-like particles: a possible indicator of immunogenicity.
    Joshi H; Cheluvaraja S; Somogyi E; Brown DR; Ortoleva P
    Vaccine; 2011 Nov; 29(51):9423-30. PubMed ID: 22027487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides.
    Fukui A; Matsueda S; Kawano K; Tsuda N; Komatsu N; Shichijo S; Sasada T; Hattori S; Ushijima K; Itoh K; Kamura T
    Virol J; 2012 Sep; 9():199. PubMed ID: 22979950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
    Schädlich L; Senger T; Kirschning CJ; Müller M; Gissmann L
    Vaccine; 2009 Mar; 27(10):1511-22. PubMed ID: 19174177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.
    Kulski JK; Sadleir JW; Kelsall SR; Cicchini MS; Shellam G; Peng SW; Qi YM; Galloway DA; Zhou J; Frazer IH
    Virology; 1998 Apr; 243(2):275-82. PubMed ID: 9568027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular variants of HPV-16 associated with cervical cancer in Indian population.
    Pillai MR; Hariharan R; Babu JM; Lakshmi S; Chiplunkar SV; Patkar M; Tongaonkar H; Dinshaw K; Jayshree RS; Reddy BK; Siddiqui M; Roychoudury S; Saha B; Abraham P; Gnanamony M; Peedicayil A; Subhashini J; Ram TS; Dey B; Sharma C; Jain SK; Singh N
    Int J Cancer; 2009 Jul; 125(1):91-103. PubMed ID: 19358280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
    Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
    J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.